AbCellera Biologics Inc

ABCL

Equity

ISIN null / Valor 58489933

NASDAQ (2026-10-09)

USD 12.54+4.37%

AbCellera Biologics Inc
UMushroom community rating:

4.00 1 votes No rating yet

NegativeNeutralPositive

About company

AbCellera Biologics Inc. is a Vancouver-based biotechnology company that develops and commercializes technologies to discover and optimize therapeutic antibodies, combining high-throughput single‑cell screening, microfluidics, next‑generation sequencing and machine‑learning analytics to identify promising human antibodies from patient samples; it works with pharmaceutical and biotech partners under research collaborations, licensing and co‑development agreements, generating revenue from upfront fees, research payments, milestones and potential royalties. The firm positions its platform to accelerate programs across infectious disease, oncology and immunology, and gained public attention for its role in identifying a COVID‑19 therapeutic antibody developed with a pharmaceutical partner. AbCellera is publicly traded and operates as a service and platform provider to companies seeking to shorten antibody discovery timelines rather than as a classical drug commercializer.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

112%1Y

185%3Y

-18.4%5Y

Performance

83.2%1Y

72.7%3Y

68.6%5Y

Volatility